论文部分内容阅读
目的 检测肝门部胆管癌新鲜组织中多药耐药基因(mdr-1)mRNA表达,探讨其与肝门部胆管癌临床病理间的关系.方法 应用逆转录聚合酶链反应(RT-PCR)对26例术前未作化疗的肝门部胆管癌和12例正常胆管mdr-1 mRNA进行了检测,并与癌组织的分化程度、病理类型、部位、浸润转移作对比研究.结果 26例肝门部胆管癌组织中mdr-1 mRNA阳性表达率为65.4%(17/26),正常胆管组织表达率为8.3%(1/12),二者差异有显著性(P<0.01).mdr-1 mRNA阳性表达与肝门部胆管癌的分化程度、发生部位、病理类型、浸润转移无关(P>0.05).结论 肝门部胆管癌中有mdr-1 mRNA的高表达,mdr-1阳性可做为肝门部胆管癌化疗耐药的指标.
Objective To detect the expression of multidrug resistance gene (mdr-1) mRNA in fresh tissues of hilar cholangiocarcinoma and explore its relationship with clinical pathology of hilar cholangiocarcinoma. Methods Reverse transcription polymerase chain reaction (RT-PCR) Twenty-six cases of preoperative non-chemotherapy hilar cholangiocarcinoma and 12 cases of normal bile duct mdr-1 mRNA were detected and compared with the differentiation, pathological type, location, invasion and metastasis of cancer tissue. Results 26 cases of liver The positive expression rate of mdr-1 mRNA was 65.4% (17/26) in normal cholangiocarcinoma and 8.3% (1/12) in normal bile duct tissue. The difference was significant (P<0.01). mdr- 1 mRNA expression was not related to the degree of differentiation, location, pathological type, infiltration and metastasis of hilar cholangiocarcinoma (P>0.05). Conclusion High expression of mdr-1 mRNA in hilar cholangiocarcinoma, mdr-1 positive As an indicator of chemotherapy resistance in hilar cholangiocarcinoma.